Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash & Equivalents (2016 - 2026)

Anika Therapeutics has reported Cash & Equivalents over the past 17 years, most recently at $41.0 million for Q1 2026.

  • Quarterly Cash & Equivalents fell 23.14% to $41.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $41.0 million through Mar 2026, down 23.14% year-over-year, with the annual reading at $57.5 million for FY2025, 3.33% up from the prior year.
  • Cash & Equivalents was $41.0 million for Q1 2026 at Anika Therapeutics, down from $57.5 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $91.4 million in Q2 2022 and troughed at $41.0 million in Q1 2026.
  • The 5-year median for Cash & Equivalents is $65.1 million (2023), against an average of $67.8 million.
  • Year-over-year, Cash & Equivalents decreased 28.8% in 2023 and then grew 3.33% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $86.3 million in 2022, then dropped by 20.37% to $68.7 million in 2023, then dropped by 19.07% to $55.6 million in 2024, then increased by 3.33% to $57.5 million in 2025, then dropped by 28.64% to $41.0 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Cash & Equivalents are $41.0 million (Q1 2026), $57.5 million (Q4 2025), and $58.0 million (Q3 2025).